Charles Russell Speechlys advises Kreos Capital on its €15 million growth capital investment
Charles Russell Speechlys LLP advised Kreos Capital V (UK) Limited on its €15 million growth capital investment in Kiadis Pharma NV (“Kiadis Pharma”), a Dutch company listed on Euronext Amsterdam and Euronext Brussels.
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders. Its product candidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.
Kiadis Pharma announced to the market that it will use the financing to advance the development of its ATIR products, for general corporate purposes and to repay €5.3 million of existing Dutch Government Loans.
The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Senior Associate) and Amelly Kok (Associate) from our Corporate Team. Fruytier Lawyers in Business advised on matters of Dutch law and Borden Ladner Gervais LLP on matters of Canadian law respectively.
News & Insights
Charles Russell Speechlys present at EIS Association Autumn Technical Seminar 2020
Our presentation covered the tax and corporate considerations for companies preparing for a possible exit.
Charles Russell Speechlys advises the owners of Safeonline LLP on its sale to Howden Broking Group Limited
Safeonline LLP has a proprietary insurtech platform, iQ, which will offer the capability to provide cyber insurance capability.
Charles Russell Speechlys advises Emergex Vaccines on $11m fundraising
Emergex is a UK-based biotechnology company and pioneers of developing synthetic ‘set point’ vaccines .